Neuroendocrine and Radioligand Therapy
The sponsor is active in neuroendocrine tumours, including SSTR-positive tumours, NET, and related metastatic disease, with interest in targeted radionuclide approaches and molecular imaging.
- 177Lu-DOTATOC and other radioreceptor therapy approaches
- PSMA PET/CT-positive advanced and metastatic tumours
- Pheochromocytomas and paragangliomas
Research activity also includes tumours retreated with PRRT and other advanced endocrine-related malignancies.
Prostate Cancer and Metastatic Bone Disease
Clinical research covers advanced prostate carcinoma, especially metastatic castration-resistant prostate cancer, with emphasis on disease control, skeletal complications, and imaging-guided treatment selection.
- mCRPC
- symptomatic bone-only metastatic disease
- oligometastatic prostate carcinoma
Its portfolio also includes studies combining systemic and local approaches for metastatic progression and bone-dominant disease.
Gastrointestinal and Colorectal Cancer
The sponsor funds trials in metastatic colorectal cancer and stage IV colorectal cancer, with attention to refractory disease and post-surgical settings.
- refractory metastatic colorectal cancer
- stage IV colorectal cancer
- mismatch-repair-proficient and microsatellite-stable disease
Related work also extends to solid tumours requiring imaging-based assessment and sequential treatment strategies.
Immunotherapy and Cell-Based Vaccination
A major area of interest is immuno-oncology, including dendritic cell vaccine strategies and combinations with other systemic therapies across multiple tumour types.
- glioblastoma
- advanced mesothelioma
- acute myeloid leukemia
This includes research in refractory and relapsed malignancies, as well as vaccine-based approaches after tumour resection.
Neuro-oncology, Leukemia, and Rare Solid Tumours
The sponsor also supports studies in aggressive and rare cancers, spanning glioblastoma, acute myeloid leukemia, mesothelioma, and soft tissue sarcoma.
- glioblastoma
- acute myeloid leukemia
- soft tissue sarcoma
Additional interest is seen in extensive-stage small-cell lung cancer and other advanced solid tumours with limited treatment options.
